Mutations in PIK3CA Sensitize Breast Cancer Cells to Physiologic Levels of Aspirin.
Marmara University, School of Medicine Department of Medical Biology, Istanbul, Turkey E-mail : ebubekir.dirican@marmara.edu.tr;ebubekirdirican44@gmail.com.
Ebubekir
E
Dirican
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D058534:Class I Phosphatidylinositol 3-Kinases; D005260:Female; D006801:Humans; D009154:Mutation / Q000235:genetics*; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics*; D011379:Prognosis
D000894:Anti-Inflammatory Agents, Non-Steroidal; D019869:Phosphatidylinositol 3-Kinases; D058534:Class I Phosphatidylinositol 3-Kinases; C484760:PIK3CA protein, human; D001241:Aspirin